^
Association details:
| Biomarker: | STRN-ALK rearrangement |
|---|---|
| Cancer: | Mesothelioma |
| Drug: | Zykadia (ceritinib) (ALK inhibitor) + gedatolisib (PF-05212384) (mTOR inhibitor, PI3K inhibitor, mTORC1 inhibitor, mTORC2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells
Published date:
01/30/2021
Excerpt:
Targeting MEK and ALK or MEK and PI3K/mTOR synergistically inhibits FM-MPeM-01 PDCs growth....strong synergy between ALK inhibitors (crizotinib and ceritinib) in combination with MEK (cobimetinib) and mTOR/PI3K (gedatolisib) inhibitors, respectively (Fig. 4). The synergy was more efficient for ceritinib compared to crizotinib. These results highlight the potential efficacy of these combinations in ALK-positive MPeM cancer treatment...
DOI:
https://doi.org/10.1016/j.tranon.2021.101027
